[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371401-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371401-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-and-comparison-of-prognostic-multigene-tests-in-early-stage-breast-cancer-which-is-the-most-effective-a-literature-review","Evaluation and Comparison of Prognostic Multigene Tests in Early-Stage Breast Cancer - Which Is the Most Effective? A Literature Review","","Breast cancer remains a highly heterogeneous disease where molecular subtype and prognosis directly influence therapeutic choices. Routine classification often relies on immunohistochemistry (IHC) using markers such as ER, PR, HER2, and Ki67, yet limitations—especially in Ki67 assessment—can lead to misclassification and inappropriate treatment. Multigene prognostic tests (e.g., Oncotype Dx, MammaPrint, Prosigna, Endopredict, Breast Cancer Index) use gene expression profiles to refine recurrence risk, help identify patients who may safely avoid chemotherapy and/or prolonged endocrine therapy, and guide decision-making in the clinical “gray zone.” This review analyzes established genomic assays, their procedures, validity, utility, and clinical frameworks, highlighting differences in comparative performance and emphasizing that genomic results should complement, not replace, clinical factors and patient preferences.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-and-comparison-of-prognostic-multigene-tests-in-early-stage-breast-cancer-which-is-the-most-effective-a-literature-review/371401/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-and-comparison-of-prognostic-multigene-tests-in-early-stage-breast-cancer-which-is-the-most-effective-a-literature-review/371401.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why can immunohistochemistry (IHC) lead to misclassification in early-stage breast cancer?","Question",{"text":63,"@type":64},"IHC-based classification uses markers such as ER, PR, HER2, and Ki67, but recognized limitations—particularly related to Ki67 evaluation—can cause incorrect subtype assignment. This may result in inappropriate therapy decisions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do multigene prognostic tests (MPTs) play in treatment selection?",{"text":68,"@type":64},"MPTs assess gene expression profiles to estimate recurrence risk more precisely. They support personalized treatment choices, helping identify patients who may avoid chemotherapy and/or extended endocrine therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"Which multigene tests are highlighted as having evidence for clinical validation, and how do they differ?",{"text":72,"@type":64},"The review notes that only Oncotype Dx and MammaPrint have prospective validation, while Prosigna adds prognostic information by incorporating clinical variables. Significant differences exist among the available tests, particularly in the clinical “gray zone.”","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371401,1790225551,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Molecular Carcinogenesis  \nBRIEF COMMUNICATION   \nEvaluation and Comparison of Prognostic Multigene Tests in Early‐Stage Breast Cancer: Which Is the Most Effective? A Literature Review Exploring Clinical Utility to Enhance Therapeutic Management in Luminal Patients  \nMarianna Rita Brogna  | Gerardo Ferrara | Valeria Varone | Angela Montone | MariaRosaria Schiano | Michele DelSesto | Francesca Collina  \nPathology Unit, Istituto Nazionale Tumori‐IRCCS‐Fondazione G. Pascale, Naples, Italy Correspondence: Marianna Rita Brogna ([brognamarianna@gmail.com](brognamarianna@gmail.com))  \nReceived: 25 November 2024 | Accepted: 3 February 2025  \nFunding: This study was supported by Ministry of Health.  \nKeywords: breast cancer | decision‐making process | gene expression profile | multigene prognostic assay | personalized medicine  \nABSTRACT  \nBreast cancer is the most common malignancy affecting women, marked by significant complexity and heterogeneity. This disease includes multiple subtypes, each with unique biological features and treatment responses. Despite significant advancements in detection and therapy, challenges remain, particularly in managing aggressive forms like triple‐negative breast cancer and overcoming drug resistance. Breast cancer classification and subtype determination are typically performed by immunohistochemistry (IHC) method, which assesses four key markers (ER, PR, HER2, KI67); however, due to the recognized issues with this approach—especially regarding the evaluation of Ki67—there is a risk of misclassification. Patients who may be suitable for chemotherapy could miss possible advantages and only experience needless toxicity as a result of improper treatment decisions. Molecular profiling has improved breast cancer management, enabling the creation of multigene prognostic tests (MPTs) like Oncotype Dx, MammaPrint, Prosigna, Endopredict, and Breast Cancer Index which assess gene expression profiles to more accurately predict recurrence risks. These tools help personalize treatment, identifying patients who can avoid chemotherapy and/or extended endocrine therapy. While many MPTs are available, only Oncotype Dx and MammaPrint have prospective validation, with Prosigna providing additional prognostic insights by incorporating clinical variables. Molecular tests are especially usefull in the “gray zone,” which includes tumors measuring between 1 and 3 cm with 0–3 positivelymph nodes and an intermediate proliferation index. However, their clinical utility has not been definitively established, and significant differences exist between them. This article provides an in‐depth analysis of established genomic assays, including testing procedures, clinical validity, utility, diagnostic frameworks, and methodologies. Our comparison aims to improve early breast cancer management by guiding pathologists and oncologists in optimizing the use of genomic assays in clinical practice. By presenting this information, we aim to enhance understanding of the clinical utility and effectiveness of these assays, supporting the development of personalized treatment strategies for early breast cancer patients. Genomic assays offer important insights that can support treatment decisions in early‐stage breast cancer, especially when used alongside other clinical evaluations, predictive tools, and management guidelines. While multiple gene expression profiling tests are available, they classify patients differently and are not interchangeable; therefore, their application should be at the clinician's discretion  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . Molecular Carcinogenesis published by Wiley Periodicals LLC.  \nMolecular Carcinogenesis, 2025; 64:789–800 789 of 953  \n[https://doi.org/10.1002/mc.23893](https://doi.org/10.1002/mc.23893)  \nduring the decis","cbCaikBW46yAVEIK","https://ap.wps.com/l/cbCaikBW46yAVEIK","pdf",1113335,12,"English","# Introduction\n## Breast cancer heterogeneity and clinical impact\n## Limitations of immunohistochemistry\n## Molecular profiling and multigene prognostic tests\n# Comparison of multigene prognostic assays","[{\"question\":\"Why can immunohistochemistry (IHC) lead to misclassification in early-stage breast cancer?\",\"answer\":\"IHC-based classification uses markers such as ER, PR, HER2, and Ki67, but recognized limitations—particularly related to Ki67 evaluation—can cause incorrect subtype assignment. This may result in inappropriate therapy decisions.\"},{\"question\":\"What role do multigene prognostic tests (MPTs) play in treatment selection?\",\"answer\":\"MPTs assess gene expression profiles to estimate recurrence risk more precisely. They support personalized treatment choices, helping identify patients who may avoid chemotherapy and/or extended endocrine therapy.\"},{\"question\":\"Which multigene tests are highlighted as having evidence for clinical validation, and how do they differ?\",\"answer\":\"The review notes that only Oncotype Dx and MammaPrint have prospective validation, while Prosigna adds prognostic information by incorporating clinical variables. Significant differences exist among the available tests, particularly in the clinical “gray zone.”\"}]","Evaluation and Comparison of Prognostic Multigene Tests in Early-Stage Breast Cancer - Which Is the Most Effective? A Literature Review | PDF",1790191988,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea98f3297eca48c93431f43628595e34.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9471c4226ad12ed5d214c191167ec69c.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d995867b0496e6f373655ea957b5211d.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04678181d5d3cb7fb4fb4abaf963e7a4.webp",980,1287]